share_log

Guggenheim Downgrades Aerovate Therapeutics to Neutral

Benzinga ·  Jun 19 00:51

Guggenheim analyst Vamil Divan downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Neutral.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment